التفاصيل البيبلوغرافية
| العنوان: |
血清 CXCL9 和 IL-34 水平检测对多发性骨髓瘤患者的 疗效监测及其预后价值. (Chinese) |
| العنوان البديل: |
Serum CXCL9 and IL-34 Levels in Multiple Myeloma Patients for Monitoring Efficacy and Prognostic Value. (English) |
| المؤلفون: |
任 梅, 石培民, 谢 静, 季 国, 李 娟, 叶春美, 许 荟 |
| المصدر: |
Journal of Modern Laboratory Medicine; Sep2023, Vol. 38 Issue 5, p127-132, 6p |
| مصطلحات موضوعية: |
SURVIVAL rate, SERUM albumin, LACTATE dehydrogenase, MULTIPLE myeloma, RECEIVER operating characteristic curves, REGRESSION analysis |
| الملخص (بالإنجليزية): |
Objective To investigate the expression of C-X-C motif chemokine ligand 9 (CXCL9) and interleukin-34 (IL-34) in the serum of patients with multiple myeloma (MM) and their diagnostic value in diagnosis, efficacy monitoring and prognosis. Methods A total of 101 patients with MM who were treated in Taixing People’s Hospital from June 2017 to January 2019 were selected as the study group, and 95 volunteers for physical examination were selected as the control group. The levels of CXCL9 and IL-34 were detected by ELISA，the diagnostic value of CXCL9 and IL-34 in serum for MM was evaluated by ROC curve. Kaplan-Meier method was used to analyze the relationship between the expression of CXCL9, IL-34 and the survival time of MM patients. Multivariate COX regression risk model was applied to analyze the factors affecting the prognosis of MM patients. Results Compared with the control group, the serum levels of CXCL9 (950.56±180.11 pg/ml vs 273.03±50.19 pg/ml) and IL34 (15.53±4.26 pg/ml vs 3.05±0.81 pg/ml) in MM patients were increased, the difference was statistically significant (t=35.391，28.077, all P<0.05). Compared with before chemotherapy, serum CXCL9 (341.21±44.76 pg/ml vs 923.21±175.78 pg/ml) and IL-34 expression levels (4.21±0.59 pg/ml vs 14.96±4.10 pg/ml) decreased in patients in the treatment-benefited group after chemotherapy, with statistically significant differences (t=44.746，32.924,all P<0.05), and serum CXCL9 (774.83±169.45pg/ml vs 999.95±187.93pg/ml) and IL-34 expression levels (12.17±3.65pg/ml vs 16.57±4.55pg/ml) decreased in patients in the treatment-naive group after chemotherapy, with statistically significant difference (t=13.692，11.365, all P<0.05). Serum expression levels of CXCL9 and IL-34 were lower in patients in the treatment-benefit group after chemotherapy compared to the treatment-naive group (t=19.508，17.247, all P<0.05). The expression of CXCL9 and IL-34 in serum of MM patients was related to D-S stage，ISS，R-ISS，lactate dehydrogenase (LDH)， serum albumin and serum calcium (t=3.029 ～ 7.219, all P<0.05). ROC results showed that the area under curve (AUC) of CXCL9 and IL-34 in diagnosing MM patients was 0.841 and 0.869 respectively, with corresponding sensitivity of 92.08% and 84.16%, specificity of 83.16% and 91.58%, respectively. The AUC of MM patients diagnosed by the two methods was 0.915, the corresponding sensitivity and specificity was 94.06% and 74.74%, respectively. Kaplan-Meier analysis showed that the 3-year cumulative survival rate of patients with low CXCL9 expression was 81.40% (35/43), which was greatly higher than 58.62% (34/58) of patients with high CXCL9 expression (Log rank χ ² =6.580, P=0.010). The 3-year cumulative survival rate of patients with low IL-34 expression was 79.17% (38/48), which was greatly higher than that of patients with high IL-34 expression 58.49% (31/53) (Log rank χ 2 =5.658, P=0.017). The analysis result of multifactor COX risk regression model showed that CXCL9, IL-34, β2-microglobulin, serum calcium, serum creatinine and LDH were independent risk factors affecting the prognosis of MM patients (P<0.05).Conclusion CXCL9 and IL-34 were highly expressed in the serum of patients with MM. The expression of CXCL9 and IL-34 has a high auxiliary value for efficacy monitoring, diagnosis and prognosis evaluation of MM patients. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): |
的 探讨C-X-C基序趋化因子配体 9(C-X-C motif chemokine ligand 9,CXCL9)和白细胞介素-34(interleukin-34,IL-34)在多发性骨髓瘤(multiple myeloma, MM)患者血清中的表达及其诊断、疗效监测、预后诊断价值.方法 选取 2017 年 6 月～2019 年 1 月在泰兴市人民医院进行治疗的MM患者 101 例为研究组,另纳入进行健康体检的志愿者 95 例为对照组.采用酶联免疫法检测CXCL9 和IL-34 水平;利用受试者工作特征(receiver operating characteristic, ROC)曲线评价血清CXCL9 和IL-34 水平对MM的诊断价值;利用Kaplan-Meier法分析MM患者血清中CXCL9 和IL-34 表达与患者生存时间的关系;采用多因素COX回归风险模型分析影响MM患者预后的因素.结果 与对照组比较,MM患者血清中CXCL9(950.56±180.11 pg/ml vs 273.03±50.19 pg/ml)和IL-34(15.53±4.26 pg/ml vs 3.05±0.81 pg/ml)表达水平升高,差异具有统计学意义(t=35.391,28.077,均P＜0.05);与化疗前比较,治疗获益组化疗后患者血清CXCL9(341.21±44.76 pg/ml vs 923.21±175.78 pg/ml)和IL-34 表达水平(4.21±0.59 pg/ml vs 14.96±4.10 pg/ml)下降,差异具有统计学意义(t=44.746,32.924,均P＜0.05);治疗未获益组化疗后患者血清CXCL9(774.83±169.45 pg/ml vs 999.95±187.93 pg/ml)和IL-34表达水平(12.17±3.65 pg/ml vs16.57±4.55 pg/ml)下降,差异具有统计学意义(t=13.692,11.365,均P＜0.05);与治疗未获益组相比,治疗获益组患者化疗后血清中CXCL9,IL-34 表达水平均较低(t=19.508,17.247,均P＜0.05);MM患者血清中CXCL9 和IL-34 表达与D-S分期、ISS,R-ISS,乳酸脱氢酶(lactate dehydrogenase, LDH)、清蛋白和血钙有关(t=3.029～7.219,均P＜0.05);ROC结果显示,CXCL9和IL-34诊断MM患者的曲线下面积(area under curve, AUC)分别为0.841,0.869;对应的敏感度分别为92.08%,84.16%;特异度分别为83.16%,91.58%.二者联合诊断MM患者的AUC为0.915,对应的敏感度和特异度分别为 94.06%,74.74%;Kaplan-Meier分析结果显示,CXCL9 低表达组患者三年累积生存率 81.40%(35/43)显著高于高表达组的 58.62%(34/58),差异有统计学意义(Log rank χ²=6.580,P=0.010).IL-34 低表达组患者三年累积生存率 79.17%(38/48)显著高于高表达组的 58.49%(31/53),差异有统计学意义(Log rank χ²=5.658,P=0.017);多因素COX风险回归模型分析结果显示,CXCL9,IL-34,β2-微球蛋白、血钙、血肌酐和LDH均为影响MM患者预后的独立危险因素(P＜0.05).结论 MM患者血清中CXCL9 和IL-34 均呈高表达,二者表达对MM患者的疗效监测、诊断及预后评估具有较高的辅助价值. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Modern Laboratory Medicine is the property of Journal of Modern Laboratory Medicine Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
